Send to a Friend Font Size: Increase Decrease

OrbiMed Advisors

OrbiMed Advisors's Portfolio

Last Updated on 5/16/11 @ 11:13am

Ticker	# of Shares	Price	Value
	73,114,592	$195.32	$14,280,742,110
	22,362,850	$195.32	$4,367,911,862
	17,233,668	$195.32	$3,366,080,034
	14,567,176	$195.32	$2,845,260,817
	9,033,726	$195.32	$1,764,467,363
	8,998,338	$195.32	$1,757,555,379
	8,322,140	$195.32	$1,625,480,385
	8,009,729	$195.32	$1,564,460,269
	7,619,135	$195.32	$1,488,169,449
View Additional Portfolio Information »

http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.

Login to help us fill in information about this entity.

View Older Stories View More Recent Stories

Mar 20, 2025 11:05AM Heng Ren Partners Demands Sinovac Distribute $8.9 Billion in Cash to its Shareholders and Cause Reinstatement of Trading
Mar 12, 2025 09:34PM Form 4 Disc Medicine, Inc. For: Mar 10 Filed by: ORBIMED ADVISORS LLC
Mar 12, 2025 07:58PM Form SCHEDULE 13D/A Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Mar 10, 2025 06:47PM Form 144 Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Mar 10, 2025 06:45PM Form 144 Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Mar 10, 2025 06:44PM Form 144 Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 14, 2025 04:39PM Form SCHEDULE 13G ADC Therapeutics SA Filed by: ORBIMED ADVISORS LLC
Feb 14, 2025 04:36PM Form SCHEDULE 13G RAPT Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 14, 2025 04:31PM Form SCHEDULE 13G/A Corbus Pharmaceuticals Filed by: ORBIMED ADVISORS LLC
Feb 14, 2025 04:24PM Form SCHEDULE 13G Forte Biosciences, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 14, 2025 04:07PM Form 13F-HR ORBIMED ADVISORS LLC For: Dec 31
Feb 13, 2025 04:48PM Form SCHEDULE 13D Sionna Therapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 10, 2025 04:29PM Form 4 Sionna Therapeutics, For: Feb 10 Filed by: ORBIMED ADVISORS LLC
Feb 6, 2025 09:18PM Form 3 Sionna Therapeutics, For: Feb 06 Filed by: ORBIMED ADVISORS LLC
Jan 29, 2025 06:43PM Form SCHEDULE 13D/A Traws Pharma, Inc. Filed by: ORBIMED ADVISORS LLC
Jan 27, 2025 07:04PM Form 4 Traws Pharma, Inc. For: Dec 29 Filed by: ORBIMED ADVISORS LLC
Jan 14, 2025 05:17PM Form 4 Passage BIO, Inc. For: Jan 10 Filed by: ORBIMED ADVISORS LLC
Jan 8, 2025 06:10PM Form 4 Passage BIO, Inc. For: Jan 06 Filed by: ORBIMED ADVISORS LLC
Jan 6, 2025 04:57PM Form 144 Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 26, 2024 04:34PM Form 4 Passage BIO, Inc. For: Dec 20 Filed by: ORBIMED ADVISORS LLC
Dec 26, 2024 04:31PM Form SCHEDULE 13D/A Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
Dec 11, 2024 05:33PM Form 4 Passage BIO, Inc. For: Dec 09 Filed by: ORBIMED ADVISORS LLC
Dec 6, 2024 07:08PM Form 4 Passage BIO, Inc. For: Dec 04 Filed by: ORBIMED ADVISORS LLC
Dec 4, 2024 07:03PM Form 144 Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
Nov 25, 2024 07:00AM Adcendo ApS Completes Oversubscribed $135 Million Series B Financing to Advance First-in-class ADC Pipeline
Nov 14, 2024 07:25PM Form SC 13G/A Scholar Rock Holding Filed by: ORBIMED ADVISORS LLC
Nov 14, 2024 07:23PM Form SC 13G/A ALX ONCOLOGY HOLDINGS Filed by: ORBIMED ADVISORS LLC
Nov 14, 2024 06:46PM Form SC 13G/A Elevation Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
Nov 14, 2024 06:44PM Form SC 13G C4 Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
Nov 14, 2024 06:41PM Form SC 13G Corbus Pharmaceuticals Filed by: ORBIMED ADVISORS LLC
Nov 14, 2024 06:35PM Form SC 13G/A InspireMD, Inc. Filed by: ORBIMED ADVISORS LLC
Nov 14, 2024 06:30PM Form SC 13G/A NeuroPace Inc Filed by: ORBIMED ADVISORS LLC
Nov 14, 2024 06:26PM Form SC 13G/A Verastem, Inc. Filed by: ORBIMED ADVISORS LLC
Nov 14, 2024 06:23PM Form SC 13G Avalo Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
Nov 14, 2024 04:07PM Form 13F-HR ORBIMED ADVISORS LLC For: Sep 30
Nov 12, 2024 06:04PM Form SC 13D/A Third Harmonic Bio, Inc. Filed by: ORBIMED ADVISORS LLC
Nov 12, 2024 05:23PM Form SC 13D/A Edgewise Therapeutics, Filed by: ORBIMED ADVISORS LLC
Nov 8, 2024 07:16PM Form SC 13D Lomond Therapeutics Hold Filed by: ORBIMED ADVISORS LLC
Nov 6, 2024 04:13PM Form SC 13D/A Traws Pharma, Inc. Filed by: ORBIMED ADVISORS LLC
Oct 25, 2024 04:25PM Form SC 13D/A TELA Bio, Inc. Filed by: ORBIMED ADVISORS LLC
Oct 17, 2024 04:18PM Form 4 Upstream Bio, Inc. For: Oct 15 Filed by: OrbiMed Advisors Israel II Ltd
Oct 17, 2024 04:17PM Form SC 13D Upstream Bio, Inc. Filed by: ORBIMED ADVISORS LLC
Oct 10, 2024 08:10PM Form 3 Upstream Bio, Inc. For: Oct 10 Filed by: ORBIMED ADVISORS LLC
Oct 8, 2024 07:36PM Armentum Partners Makes Key Senior Hire in Andrew Fineberg to Expand Royalty Capabilities
Oct 1, 2024 05:35PM Form SC 13D/A TELA Bio, Inc. Filed by: ORBIMED ADVISORS LLC
Sep 23, 2024 06:45PM Form SC 13D Traws Pharma, Inc. Filed by: ORBIMED ADVISORS LLC
Sep 23, 2024 04:52PM Form 4 Passage BIO, Inc. For: Sep 19 Filed by: ORBIMED ADVISORS LLC
Sep 23, 2024 04:42PM Form 3 Traws Pharma, Inc. For: Sep 16 Filed by: ORBIMED ADVISORS LLC
Sep 23, 2024 04:34PM Form SC 13D MBX Biosciences, Inc. Filed by: ORBIMED ADVISORS LLC
Sep 18, 2024 06:38PM Form 4 Passage BIO, Inc. For: Sep 16 Filed by: ORBIMED ADVISORS LLC

View More Recent Stories View Older Stories

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed